Find Pradofloxacin manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Veraflox, 195532-12-8, Pradofloxacin [inn], 6o0t5e048i, 8-cyano-1-cyclopropyl-7-((1s,6s)-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydro-1h-pyrrolo[3,4-b]pyridin-6(2h)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
Molecular Formula
C21H21FN4O3
Molecular Weight
396.4  g/mol
InChI Key
LZLXHGFNOWILIY-APPDUMDISA-N
FDA UNII
6O0T5E048I

Pradofloxacin
Pradofloxacin is a 3rd generation fluoroquinolone antibiotic developed by Bayer HealthCare AG, Animal Health GmBH. It was approved by the European Commission in April 2011 for bacterial infections in dogs and cats.
1 2D Structure

Pradofloxacin

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
2.1.2 InChI
InChI=1S/C21H21FN4O3/c22-16-6-13-18(26(12-3-4-12)9-15(20(13)27)21(28)29)14(7-23)19(16)25-8-11-2-1-5-24-17(11)10-25/h6,9,11-12,17,24H,1-5,8,10H2,(H,28,29)/t11-,17+/m0/s1
2.1.3 InChI Key
LZLXHGFNOWILIY-APPDUMDISA-N
2.1.4 Canonical SMILES
C1CC2CN(CC2NC1)C3=C(C=C4C(=C3C#N)N(C=C(C4=O)C(=O)O)C5CC5)F
2.1.5 Isomeric SMILES
C1C[C@H]2CN(C[C@H]2NC1)C3=C(C=C4C(=C3C#N)N(C=C(C4=O)C(=O)O)C5CC5)F
2.2 Other Identifiers
2.2.1 UNII
6O0T5E048I
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Veraflox

2. 195532-12-8

3. Pradofloxacin [inn]

4. 6o0t5e048i

5. 8-cyano-1-cyclopropyl-7-((1s,6s)-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid

6. 8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydro-1h-pyrrolo[3,4-b]pyridin-6(2h)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid

7. Pudofloxacin

8. Unii-6o0t5e048i

9. Pradofloxacin [mi]

10. Schembl150884

11. Chembl1256815

12. Dtxsid60173229

13. Pradofloxacin [green Book]

14. Ex-a5917

15. Zinc3827732

16. Db11453

17. Pradofloxacin [ema Epar Veterinary]

18. A937065

19. Q15679498

20. 8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-octahydro-6h-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid

21. 8-cyano-1-cyclopropyl-7-((1s,6s)-2,8-diazabicyclo[4.3.0]-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid

22. 8-cyano-1-cyclopropyl-7-((1s,6s)-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3quinolinecarboxylic Acid

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 396.4 g/mol
Molecular Formula C21H21FN4O3
XLogP30.4
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count8
Rotatable Bond Count3
Exact Mass396.15976871 g/mol
Monoisotopic Mass396.15976871 g/mol
Topological Polar Surface Area96.7 Ų
Heavy Atom Count29
Formal Charge0
Complexity803
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

* Dogs:

Treatment of:

- wound infections caused by susceptible strains of the Staphylococcus intermedius group (including S. pseudintermedius);

- superficial and deep pyoderma caused by susceptible strains of the Staphylococcus intermedius group (including S. pseudintermedius);

- acute urinary-tract infections caused by susceptible strains of Escherichia coli and the Staphylococcus intermedius group (including S. pseudintermedius);

- as adjunctive treatment to mechanical or surgical periodontal therapy in the treatment of severe infections of the gingiva and periodontal tissues caused by susceptible strains of anaerobic organisms, for example Porphyromonas spp. and Prevotella spp.

* Cats:

Treatment of acute infections of the upper respiratory tract caused by susceptible strains of Pasteurella multocida, Escherichia coli and the Staphylococcus intermedius group (including S. pseudintermedius).


Dogs: , Infections of the skin and soft tissues, i. e. superficial and deep pyoderma and wound infections caused by Gram-positive organisms, typically Staphylococcus spp. and Streptococcus spp. , and Gram-negative organisms such as Escherichia coli, Pseudomonas spp. and Proteus spp. , Infections of the urinary tract caused by Gram-negative bacteria such as enterobacteriaceae, e. g. Escherichia coli, Enterobacter spp. , Klebsiella spp. and Proteus spp. , Pseudomonas spp. , and Gram-positive organisms, typically Staphylococcus spp. , Infections of the gingiva and periodontal tissues caused by anaerobic organisms, for example Porphyromonas spp. , Prevotella spp. ; Fusobacterium spp. , Eikenella spp. and capnophilic bacteria such as Capnocytophaga spp. , , Cats: , Infections of the respiratory tract caused by Gram-negative organisms such as Pasteurella spp. , Escherichia coli and Pseudomonas spp. , and Gram-positive organisms such as Streptococcus spp. and Staphylococcus spp. ,


5 Pharmacology and Biochemistry
5.1 ATC Code

QJ01MA97


QJ01MA


NDC API

read-more
read-more

01

Bayer AG

Germany
Medlab Asia & Asia Health
Not Confirmed
arrow

Bayer AG

Germany
arrow
Medlab Asia & Asia Health
Not Confirmed

PRADOFLOXACIN

NDC Package Code : 12527-0386

Start Marketing Date : 2021-08-09

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

02

Bayer AG

Germany
Medlab Asia & Asia Health
Not Confirmed
arrow

Bayer AG

Germany
arrow
Medlab Asia & Asia Health
Not Confirmed

PRADOFLOXACIN

NDC Package Code : 12527-0385

Start Marketing Date : 2021-08-09

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

03

Medlab Asia & Asia Health
Not Confirmed
arrow
arrow
Medlab Asia & Asia Health
Not Confirmed

PRADOFLOXACIN

NDC Package Code : 66653-011

Start Marketing Date : 2024-04-30

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty